Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 15/20 | 0.53 |
| ▸ | PLG | P00747 | 9/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.53 |
| ▸ | PLAT | P00750 | 7/20 | 0.53 |
| ▸ | F2 | P00734 | 6/20 | 0.53 |
| ▸ | KLK1 | P06870 | 2/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401550 | 0.80 | CSNK2A2 (0.42) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NPC1 | |
| SCHEMBL7335284 | 0.77 | RAB9A (0.74) | PLAUPLGKLKB1PRSS1PLAT | |
| SCHEMBL7334144 | 0.76 | NPC1 (0.74) | PLAUPLGKLKB1PRSS1PLAT | |
| SCHEMBL836669 | 0.74 | KDR (0.68) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NPC1 | |
| SCHEMBL7343145 | 0.73 | MAPT (0.68) | PLAUPLGKLKB1PRSS1PLAT | |
| SCHEMBL5835755 | 0.73 | CA2 (0.60) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29908276 | 0.72 | STAT3 (0.64) | NPC1RAB9A | |
| SCHEMBL7346190 | 0.72 | PLAU (0.68) | PLAUPLGKLKB1PRSS1PLAT | |
| SCHEMBL7346846 | 0.72 | KMT2A (0.58) | PLAUPLGKLKB1PRSS1PLAT | |
| SCHEMBL18456670 | 0.72 | AURKB (0.52) | NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885PLG 10/4885KLKB1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.